Startup
Every investor coverage indicates participated in a round Telethon Kids Institute raised.
| Investor | Rounds | Invested |
|---|---|---|
| Brandon BioCatalyst | Accelerator | - |
| WA Future Health Research and Innovation Fund | Accelerator | - |
Companies Telethon Kids Institute acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
| Name | Role | Sources |
|---|---|---|
| A/Prof Anthony Kicic | Innovation Team Lead | @AuManufacturing |
| A/Prof Jenny Downs | Innovation Team Lead | @AuManufacturing |
| A/Prof Joost Lesterhuis | Innovation Team Lead | @AuManufacturing |
| Dr Elke Seppanen | Microbiologist | @AuManufacturing |
| Dr Lea-Ann Kirkham | Microbiologist | @AuManufacturing |
| Prof Terrance Johns | Innovation Team Lead | @AuManufacturing |
| Professor Jonathan Carapetis | Executive Director | Brandon Capital, Brandon BioCatalyst |
| Simone Knox | Media and Content Manager | Brandon Capital, Brandon BioCatalyst |
Stories naming Telethon Kids Institute. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
A Telethon Kids spin-out backed by Brandon Capital has begun trials in the US and Australia of RSP-1502, an inhaled antibiotic booster for cystic fibrosis lung infections, after strong early results in WA patients.
A Telethon Kids offshoot, Respirion Pharmaceuticals, is trialling its antibiotic-booster therapy RSP-1502 in the US and Australia, with backing from Brandon Capital and an American cystic fibrosis foundation.
Brandon BioCatalyst's CUREator biotech incubator has allocated $3 million across five antimicrobial resistance projects, with a UWA-linked nasal spray venture, Spritz-OM, receiving $500,000 toward Phase 1 clinical trials.
Profile of Cairns startup Rainstick, which uses artificial lightning to boost mushroom growth. It won $20,000 from Dream Ventures, has taken in $200,000, and joined CSIRO's ON Accelerate with nine other teams.
CSIRO has revived its ON Accelerate program and named ten deep-tech startup teams, drawn from universities and its own research, joining the seventh cohort starting in early 2023.
West Australian medtech Avicena won government approval to trial its Sentinel rapid saliva screening system among fly-in fly-out resources workers; the piece also recalls two earlier state grants supporting the technology's development.
Plus Eight has selected eight Western Australian startups from 70 applicants to share a $350,000 investment pool, advancing them to the seed-funding stage after a bootcamp, mentoring and a pitch day.
The MRCF Biomedical Translation Fund has launched Respirion Pharmaceuticals, a Perth biotech developing an inhaled antibiotic for cystic fibrosis, committing up to A$20 million, with up to US$3 million from the CF Foundation.